The inhibition of FGF19, achieved through methods such as siRNA-mediated silencing or neutralization by an anti-FGF19 antibody, specifically decreases AKT phosphorylation, suppresses cancer cell growth, and enhances doxorubicin sensitivity in FGFR4+/FGF19+ BC cells 46. The gene discussed is FGFR4; the disease is breast cancer.